United-Guardian, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. United-Guardian manufactures and markets cosmetic ingredients, pharmaceuticals, and medical lubricants through its Guardian Laboratories division. The company’s principal products include Lubrajel, Renacidin, and Clorpactin.
Financial performance
| Metric | Q2 2023 | Q2 2022 | First half 2023 | First half 2022 |
|---|---|---|---|---|
| Net sales | $2.65 million | $3.63 million | $5.22 million | $7.52 million |
| Income from operations | $518,070 | $1,199,929 | $1,349,894 | $2,703,755 |
| Net income | $461,094 | $633,324 | $1,217,175 | $1,544,789 |
| Basic and diluted EPS | $0.10 | $0.14 | $0.26 | $0.34 |
| Operating cash flow | Not separately reported | Not separately reported | $852,247 | $1,164,601 |
Net sales declined 27% in Q2 and 31% in the first half. Net income declined 27% and 21%, respectively. Gross margin was approximately 46% in Q2 2023 versus 53% a year earlier, and 52% for the first half versus 55%. Operating margin was approximately 19.5% in Q2 versus 33.1%, and 25.9% for the first half versus 36.0%.
At June 30, cash and cash equivalents were $6.48 million, marketable securities $939,576, and current assets $11.36 million. Working capital was $10.01 million and the current ratio was 8.4:1. Total liabilities were approximately $1.39 million; the balance sheet reports no debt. First-half cash increased $5.65 million, primarily reflecting marketable-security sales and the timing of the semiannual dividend. No dividends were paid in the first half of 2023; the company shifted declaration and payment to Q3. Capital spending was $3,912.
Material changes and drivers
- Cosmetic ingredient sales fell 45% in Q2 and 56% in the first half. The largest distributor, Ashland Specialty Ingredients, reported weaker demand, especially in China, lower-priced competition, customer destocking, and changed ordering patterns.
- Medical lubricant sales declined 50% in Q2 and 41% in the first half, largely because a major Chinese customer reduced orders after overstocking during China’s zero-COVID period.
- Pharmaceutical gross sales rose 10% in Q2 and 6% in the first half, primarily due to Renacidin price increases and ordering patterns. Pharmaceutical net sales were also affected by rebates, fees, and allowances.
- Cost of sales rose as a share of sales, reflecting a larger pharmaceutical sales mix and higher per-unit overhead from reduced production. Operating expenses decreased 7% in Q2 and 6% in the first half; R&D expense increased 15% and 5%, respectively.
- Marketable securities generated net gains of $7,479 in Q2 and $80,180 in the first half, compared with losses of $460,278 and $853,938 in the comparable 2022 periods. The company sold most of its fixed-income mutual funds during Q2 2023; the filing also reports $433,769 of realized losses on securities sold in the first half.
Outlook, risks, and other notable items
Management expects available working capital to support operations for at least 12 months and intends to use cash for organic growth, potential strategic transactions, and dividends. The company expects a 21% tax rate for 2023. It is upgrading its building sprinkler system, with expected costs of approximately $100,000 during the remainder of 2023.
Management says it cannot reliably estimate the future effects of residual pandemic impacts, supply-chain instability, and inflation. Higher raw-material, shipping, and labor costs may pressure margins; price increases have been implemented where possible. China demand weakness, competition, distributor/customer concentration, and investment-market volatility are additional concerns. Four distributors accounted for 81% of Q2 sales and 84% of receivables at June 30. The industrial product line was phased out, with Q2 2023 its final reported sales period.
The company adopted the CECL credit-loss standard in January 2023 with no material financial-statement effect. Management reported effective disclosure controls and no material change in internal control over financial reporting. The filing reports no legal proceedings and lists no separate Part II risk factors. A $60,000 first-half consulting payment to former President Ken Globus is disclosed as a related-party transaction.
Important facts for investors to verify
- Whether distributor and customer ordering patterns, China demand, and competitive pricing improve, particularly for cosmetic ingredients and medical lubricants.
- Whether price increases offset raw-material, shipping, labor, and lower-production costs, and how gross margins develop.
- The company’s investment portfolio composition and realized/unrealized gains or losses, given the large securities sales and year-over-year earnings volatility.
- The timing and amount of the Q3 dividend and the planned approximately $100,000 sprinkler-system expenditure.
- The persistence of distributor concentration and related receivable exposure; also confirm the filing’s reported cash, marketable-securities, and liability balances.